March 1
$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectThe Burnet Institute is an independent, not‐for‐profit Australian organization that is unique in its approach of linking medical research with public health action to address many of the major health problems affecting disadvantaged communities. This approach allows us to develop innovative health solutions ranging from the highly technological through to those that are community-based.
ViewSince its inception in 1956, the Auckland Cancer Society Research Centre (ACSRC) has published nearly 1,000 papers in international scientific and medical journals, and filed more than 100 patent applications for new anti-cancer drugs.
ViewThe Baker Heart and Diabetes Institute is an independent, internationally renowned medical research facility, with a history spanning more than 93 years. The Institute's work extends from the laboratory to wide-scale community studies with a focus on diagnosis, prevention and treatment of diabetes and cardiovascular disease.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn more$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Read moreAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Read moreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
Read more